Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.75% 0.04% 51.39M 4562.73
Weighted Average Dividend Yield Turnover Ratio (Generic) 1 Year Fund Level Flows Max Drawdown (Since Inception)
1.28% 85.00% -15.75M

Basic Info

Investment Strategy
The Fund seeks to provide long-term growth of capital by investing at least 80% of its net assets, in companies that derive at least 50% of revenues from products or services related to GLP-1 and treatment of cardiovascular diseases and/or metabolic diseases defined by Centers for Diseases Control and Preventions.
General
Security Type Exchange-Traded Fund
Equity Style Multi Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Tema
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Performance Versus Peer Group

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Peer Group Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Peer Group (NAV)
--
--
--
--
--
--
--
--

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
--
--
--
--
--
-4.30%
23.90%
-3.74%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
21.09%
-2.13%
25.24%
18.96%
3.91%
-8.62%
9.64%
7.04%
20.00%
0.54%
--
--
--
--
--
-4.66%
28.62%
1.52%
--
--
--
--
--
-1.01%
15.38%
-3.14%
--
--
-3.96%
-19.69%
5.70%
1.55%
21.79%
-4.26%
As of April 02, 2026.

Asset Allocation

As of February 28, 2026.
Type % Net
Cash 0.33%
Stock 99.25%
Bond 0.26%
Convertible 0.00%
Preferred 0.00%
Other 0.15%
View Asset Allocation
Start Trial

Basic Info

Investment Strategy
The Fund seeks to provide long-term growth of capital by investing at least 80% of its net assets, in companies that derive at least 50% of revenues from products or services related to GLP-1 and treatment of cardiovascular diseases and/or metabolic diseases defined by Centers for Diseases Control and Preventions.
General
Security Type Exchange-Traded Fund
Equity Style Multi Cap Growth
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Tema
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Top Portfolio Holders